% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • phaseiii Mar 29, 2011 1:43 PM Flag

    Analysts predict approval

    *Needham & Co.
    "Based on a successful Phase III program in C. difficile infection establishing consistent superiority to vancomycin with respect to recurrence of infection and global cure, we believe the compound is likely to receive a favorable vote, followed by approval in May."

    "...we are quite optimistic regarding the approval of fidaxomicin".
    "...we are pleased to note that fidaxomicin scores better than the current available treatment options on many parameters."

    *Hilary Kramer
    "Optimer is poised for double digit gains in 2011."
    "The big pharmaceutical companies are in desperate need for new blockbusters, ... we are going to see big pharma wanting a company like Optimer... it could be acquired at around $17 to $19 dollars a share. There is opportunities for billions of dollars of sales around the world for the drug to fight this

    "Jefferies believes the upcoming FDA panel and PDUFA for Optimer Pharmaceuticals' fidaxomicin are likely to be positive and finds the stock inexpensive at current levels."

    *Adam Feuerstein
    "Overall, the fidamoxicin data generated across two, large phase III studies are strong and should support a positive vote at next week's panel and full approval by the FDA on May 30."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
12.780.00(0.00%)Oct 23 4:00 PMEDT